6
|
Johansen SS, Wang X, Sejer Pedersen D, Pearl PL, Roullet JB, Ainslie GR, Vogel KR, Gibson KM. Gamma-Hydroxybutyrate (GHB) Content in Hair Samples Correlates Negatively with Age in Succinic Semialdehyde Dehydrogenase Deficiency. JIMD Rep 2017; 36:93-98. [PMID: 28213850 DOI: 10.1007/8904_2017_3] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Revised: 01/02/2017] [Accepted: 01/05/2017] [Indexed: 12/13/2022] Open
Abstract
Gamma-hydroxybutyrate (GHB) is a drug of abuse, an approved therapeutic for narcolepsy, an agent employed for facilitation of sexual assault, as well as a biomarker of succinic semialdehyde dehydrogenase deficiency (SSADHD). Our laboratory seeks to identify surrogate biomarkers in SSADHD that can shed light on the developmental course of this neurometabolic disease. Since GHB may be quantified in hair as a potential surrogate to identify victims of drug-related assault, we have opted to examine its level in SSADHD. We quantified GHB in hair derived from ten patients with SSADHD, and documented a significant negative age correlation. These findings are consistent with recent results in patient biological fluids, including plasma and red blood cells. These findings may provide additional insight into the developmental course of SSADHD (Jansen et al., J Inherit Metab Dis 39:795-800, 2016).
Collapse
Affiliation(s)
- S S Johansen
- Section of Forensic Chemistry, Department of Forensic Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - X Wang
- Section of Forensic Chemistry, Department of Forensic Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - D Sejer Pedersen
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - P L Pearl
- Department of Neurology, Harvard Medical School, Boston Children's Hospital, Boston, MA, USA
| | - J-B Roullet
- Section of Experimental and Systems Pharmacology, College of Pharmacy, Washington State University, Pharmaceutical and Biomedical Sciences Building, Room 347, Health Sciences Campus, 412 E. Spokane Falls Blvd., Spokane, WA, 99214, USA
| | - G R Ainslie
- Section of Experimental and Systems Pharmacology, College of Pharmacy, Washington State University, Pharmaceutical and Biomedical Sciences Building, Room 347, Health Sciences Campus, 412 E. Spokane Falls Blvd., Spokane, WA, 99214, USA
| | - K R Vogel
- Section of Experimental and Systems Pharmacology, College of Pharmacy, Washington State University, Pharmaceutical and Biomedical Sciences Building, Room 347, Health Sciences Campus, 412 E. Spokane Falls Blvd., Spokane, WA, 99214, USA
| | - K M Gibson
- Section of Experimental and Systems Pharmacology, College of Pharmacy, Washington State University, Pharmaceutical and Biomedical Sciences Building, Room 347, Health Sciences Campus, 412 E. Spokane Falls Blvd., Spokane, WA, 99214, USA.
| |
Collapse
|
7
|
Perszyk RE, DiRaddo JO, Strong KL, Low CM, Ogden KK, Khatri A, Vargish GA, Pelkey KA, Tricoire L, Liotta DC, Smith Y, McBain CJ, Traynelis SF. GluN2D-Containing N-methyl-d-Aspartate Receptors Mediate Synaptic Transmission in Hippocampal Interneurons and Regulate Interneuron Activity. Mol Pharmacol 2016; 90:689-702. [PMID: 27625038 PMCID: PMC5118640 DOI: 10.1124/mol.116.105130] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Accepted: 09/12/2016] [Indexed: 12/29/2022] Open
Abstract
N-methyl-d-aspartate receptors (NMDARs) are ionotropic glutamatergic receptors that have been implicated in learning, development, and neuropathological conditions. They are typically composed of GluN1 and GluN2A-D subunits. Whereas a great deal is known about the role of GluN2A- and GluN2B-containing NMDARs, much less is known about GluN2D-containing NMDARs. Here we explore the subunit composition of synaptic NMDARs on hippocampal interneurons. GluN2D mRNA was detected by single-cell PCR and in situ hybridization in diverse interneuron subtypes in the CA1 region of the hippocampus. The GluN2D subunit was detectable by immunoblotting and immunohistochemistry in all subfields of the hippocampus in young and adult mice. In whole-cell patch-clamp recordings from acute hippocampal slices, (+)-CIQ, the active enantiomer of the positive allosteric modulator CIQ, significantly enhanced the amplitude of the NMDAR component of miniature excitatory postsynaptic currents (mEPSCs) in CA1 interneurons but not in pyramidal cells. (+)-CIQ had no effect in slices from Grin2d-/- mice, suggesting that GluN2D-containing NMDARs participate in excitatory synaptic transmission onto hippocampal interneurons. The time course of the NMDAR component of the mEPSC was unaffected by (+)-CIQ potentiation and was not accelerated in slices from Grin2d-/- mice compared with wild-type, suggesting that GluN2D does not detectably slow the NMDAR EPSC time course at this age. (+)-CIQ increased the activity of CA1 interneurons as detected by the rate and net charge transfer of spontaneous inhibitory postsynaptic currents (sIPSCs) recorded from CA1 pyramidal cells. These data provide evidence that interneurons contain synaptic NMDARs possessing a GluN2D subunit, which can influence interneuron function and signal processing.
Collapse
Affiliation(s)
- Riley E Perszyk
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - John O DiRaddo
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Katie L Strong
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Chian-Ming Low
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Kevin K Ogden
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Alpa Khatri
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Geoffrey A Vargish
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Kenneth A Pelkey
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Ludovic Tricoire
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Dennis C Liotta
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Yoland Smith
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Chris J McBain
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| | - Stephen F Traynelis
- Departments of Pharmacology (R.E.P., J.O.D., K.K.O., A.K., S.F.T.), Chemistry (J.O.D., K.L.S., D.C.L.), Neurology (Y.S.), Yerkes National Primate Research Center (Y.S.), and Morris K. Udall Center of Excellence for Parkinson's Disease Research (Y.S.), Emory University, Atlanta, Georgia; Departments of Pharmacology and Anaesthesiology (C.-M.L.), Yong Loo Lin School of Medicine, National University of Singapore, Singapore; and Program in Developmental Neurobiology, Eunice Kennedy-Shriver National Institute of Child Health and Human Development (G.A.V., K.A.P., L.T., C.J.M.), National Institutes of Health, Bethesda, Maryland
| |
Collapse
|
8
|
Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR, Hamidi GA, Salami M. Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial. Front Aging Neurosci 2016; 8:256. [PMID: 27891089 PMCID: PMC5105117 DOI: 10.3389/fnagi.2016.00256] [Citation(s) in RCA: 577] [Impact Index Per Article: 64.1] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Accepted: 10/17/2016] [Indexed: 12/11/2022] Open
Abstract
Alzheimer's disease (AD) is associated with severe cognitive impairments as well as some metabolic defects. Scant studies in animal models indicate a link between probiotics and cognitive function. This randomized, double-blind, and controlled clinical trial was conducted among 60 AD patients to assess the effects of probiotic supplementation on cognitive function and metabolic status. The patients were randomly divided into two groups (n = 30 in each group) treating with either milk (control group) or a mixture of probiotics (probiotic group). The probiotic supplemented group took 200 ml/day probiotic milk containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum (2 × 109 CFU/g for each) for 12 weeks. Mini-mental state examination (MMSE) score was recorded in all subjects before and after the treatment. Pre- and post-treatment fasting blood samples were obtained to determine the related markers. After 12 weeks intervention, compared with the control group (-5.03% ± 3.00), the probiotic treated (+27.90% ± 8.07) patients showed a significant improvement in the MMSE score (P <0.001). In addition, changes in plasma malondialdehyde (-22.01% ± 4.84 vs. +2.67% ± 3.86 μmol/L, P <0.001), serum high-sensitivity C-reactive protein (-17.61% ± 3.70 vs. +45.26% ± 3.50 μg/mL, P <0.001), homeostasis model of assessment-estimated insulin resistance (+28.84% ± 13.34 vs. +76.95% ± 24.60, P = 0.002), Beta cell function (+3.45% ± 10.91 vs. +75.62% ± 23.18, P = 0.001), serum triglycerides (-20.29% ± 4.49 vs. -0.16% ± 5.24 mg/dL, P = 0.003), and quantitative insulin sensitivity check index (-1.83 ± 1.26 vs. -4.66 ± 1.70, P = 0.006) in the probiotic group were significantly varied compared to the control group. We found that the probiotic treatment had no considerable effect on other biomarkers of oxidative stress and inflammation, fasting plasma glucose, and other lipid profiles. Overall, the current study demonstrated that probiotic consumption for 12 weeks positively affects cognitive function and some metabolic statuses in the AD patients. CLINICAL TRIAL REGISTRATION http://www.irct.ir/, IRCT201511305623N60.
Collapse
Affiliation(s)
- Elmira Akbari
- Physiology Research Center, Kashan University of Medical Sciences Kashan, Iran
| | - Zatollah Asemi
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences Kashan, Iran
| | - Reza Daneshvar Kakhaki
- Department of Neurology, School of Medicine, Kashan University of Medical Sciences Kashan, Iran
| | - Fereshteh Bahmani
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences Kashan, Iran
| | - Ebrahim Kouchaki
- Department of Neurology, School of Medicine, Kashan University of Medical Sciences Kashan, Iran
| | - Omid Reza Tamtaji
- Physiology Research Center, Kashan University of Medical Sciences Kashan, Iran
| | - Gholam Ali Hamidi
- Physiology Research Center, Kashan University of Medical Sciences Kashan, Iran
| | - Mahmoud Salami
- Physiology Research Center, Kashan University of Medical Sciences Kashan, Iran
| |
Collapse
|